New Jersey: Johnson & Johnson said that the company-manufactured single-shot vaccine for COVID-19 neutralises the Delta variant and is effective in providing durable protection against the infection more broadly.
According to a Johnson & Johnson statement on Thursday, the recipients of its vaccine produced strong neutralising antibodies over the course of at least eight months against all variants including delta.
The Centers for Disease Control and Prevention in the United States said that Delta is expected to become the dominant strain in the country in the coming weeks.
“We’re extremely happy, actually, and confident there’s no need for the booster at the moment and we’re protected against different strains,” J&J’s global head of infectious diseases and vaccines, Johan Van Hoof was quoted as saying by Bloomberg in an interview.
The company said that the shot neutralised the delta variant within 29 days of a first jab, and the protection matured and improved over time.
ALSO READ: Johnson & Johnson’s Single-Dose Vaccine Likely To Be Available In India By July
